This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In particular, the study showed superiority in the percentage of patients that achieved freedom from atrialfibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone. tim.hodson Fri, 02/14/2025 - 09:57 Feb. adult population.
ObjectiveThis study aimed to investigate the effects of Enhanced External Counterpulsation (EECP) on anxiety and depression in patients with Paroxysmal AtrialFibrillation (PAF).MethodsA MethodsA cohort of 100 patients diagnosed with PAF at the Fuzhou First Hospital between January 2023 and June 2024 were enrolled in this study.
BackgroundInstant atrialfibrillation termination (AFT) during radiofrequency ablation has been suggested as a predictor of prognosis in persistent atrialfibrillation (AF). However, its role in cryoballoon ablation remains unclear. Propensity score matching (PSM) was applied to eliminate covariate imbalances.
Nature Reviews Cardiology, Published online: 25 September 2024; doi:10.1038/s41569-024-01091-1 The burden of atrialfibrillation (AF) is increasing worldwide; however, most existing data on AF epidemiology are from Western regions.
As the Diagnostic and Interventional Cardiology (DAIC) team welcomes in the New Year, we also have taken a few moments to reflect back on the Top 10 most read content from 2023. Medtronic Creates History with FDA Approval of its Novel PulseSelect Pulsed Field Ablation System to Treat AtrialFibrillation 3.
Earlier this year, clinical trial data presented demonstrated the FARAPULSE PFA System is noninferior to standard-of-care therapies for the treatment of paroxysmal AF, with superior efficiency, while additional real-world data from more than 17,000 patients demonstrated continued real-world safety, efficacy and efficiency of the system. Circulation.
Methods Relevant studies examining arrhythmia in both exercise and pharmacological stress testing were searched for in PubMed, Embase and Cochrane databases from inception to 14 June 2023. The primary outcomes of interest were mortality in ventricular and atrial arrhythmias, and later diagnosis of cardiac disease in atrial arrhythmias.
About AtrialFibrillation and Pulsed Field Ablation AF is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide3. November 2023. Mortality trends in patients diagnosed with first atrialfibrillation: a 21-year community-based study. Circulation.
In Europe, the TRUPULSE generator received CE mark in late 2023 and the VARIPULSE Catheter received CE mark in February 2024. Global epidemiology of atrialfibrillation: An increasing epidemic and public health challenge. Epidemiology of AtrialFibrillation in the 21st Century. In the U.S., Int J Stroke.
Recommendations from the “2014 AHA/ACC/HRS Guideline for the Management of Patients With AtrialFibrillation” and the “2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With AtrialFibrillation” have been updated with new evidence to guide clinicians.
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrialfibrillation procedures. Estimates of current and future incidence and prevalence of atrialfibrillation in the U.S.
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. ConclusionsComplications following atrialfibrillation ablation were associated with significant increase in length of stay and hospitalization costs, most of which were attributable to bleeding and pericardial effusion. million, 41.9%
Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023. BackgroundAn increased risk of recurrent stroke is noted in patients with atrialfibrillation despite direct oral anticoagulant (DOAC) use.
30, 2023) — The American Heart Association (AHA) and the American College of Cardiology (ACC), along with several other leading medical associations, have issued a new guideline for preventing and optimally managing atrial. DALLAS and WASHINGTON (Nov.
Background Atrialfibrillation (AF) is a common cardiac arrhythmia that increases the risk of stroke and other cardiovascular complications. Methods This web-based cross-sectional study was conducted at local Hospital between April 2023 and May 2023, and enrolled AF patients. The KAP scores were 4.64 ± 3.28, 21.09 ± 2.33
Background Cryoballoon ablation (CBA) and laser balloon ablation (LBA) are two innovative ways for the treatment of atrialfibrillation (AF). This study aimed to evaluate the efficacy and safety of cryoballoon ablation and laser balloon ablation in patients with AF.
Background Postoperative atrialfibrillation (POAF) is a frequent complication that may increase morbidity and mortality risk following cardiac surgery. In August 2023, a comprehensive literature search was performed to identify relevant studies reporting SII cutoff values with corresponding sensitivity and specificity.
Getty Images milla1cf Tue, 02/06/2024 - 20:36 February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial ( NCT05883631 ), a study formally launched in late October 2023.
Definitely atrialfibrillation. Probably WPW but is very slow for atrial fib withWPW. So this looks like WPW with Atrialfibrillation. What is unusual is that the rate is not REALLY fast, as you expect when there is atrial fib with an accessory pathway. Goyal et al — StatPearls: July, 2023 ).
An international panel of experts published recommendations to improve management of atrialfibrillation (AF). Today the consensus report was presented at the EHRA congress in Berlin by Prof.
Affecting 60 million people worldwide 1 , the prevalence of atrialfibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. tim.hodson Fri, 01/24/2025 - 11:03 Jan. 22, 2025 Anthos Therapeutics, Inc., Study completion is anticipated for the second half of 2026.
Using the Society of Thoracic Surgeons Adult Cardiac Surgery Database , the study covers adult patients who underwent cardiac surgery after an initial TAVR from January 2012 to March 2023. It emphasizes the evolving role of surgical ablation and left atrial appendage occlusion in managing atrialfibrillation.
Rhythm control with either medications or catheter ablation is an established strategy for symptomatic patients with atrialfibrillation (AF), by reducing arrhythmic burden and improving patient quality of life, as well as reducing the risk of heart failure hospitalization and mortality in select populations with concomitant AF and heart failure.
Atrialfibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation [abstract].
BackgroundSerum uric acid (SUA) and lipid metabolism disorders are closely associated with atrialfibrillation (AF) and its prognosis. We analyzed SUA concentration and lipid profile, along with relevant clinical data, to assess their impact on the occurrence of ischemic stroke (IS) in NAF patients.
Background The value of empirical superior vena cava isolation (SVCI) following pulmonary vein isolation (PVI) to improve the efficacy of radiofrequency catheter ablation (RFCA) for paroxysmal atrialfibrillation (PAF) remains controversial. RFCA was guided by quantitative AI in both groups.
AF Often Asymptomatic: Even for atrialfibrillation (AF)the most commonly symptomatic arrhythmiaover half of all cases were asymptomatic. Its estimated that undiagnosed atrialfibrillation alone costs the U.S. $3 Treasure Island (FL): StatPearls Publishing; June 5, 2023. 3 Desai et al. Arrhythmias. In: StatPearls.
28, 2025 At theAmerican College of Cardiology (ACC) 2025 meeting,GE HealthCare will introduce RevolutionVibe, i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrialfibrillation and heavily calcified coronaries.
Atrialfibrillation (AF) and premature ventricular complexes (PVCs) are common arrhythmias associated with significant morbidity and mortality.1,2 Atrialfibrillation (AF) and premature ventricular complexes (PVCs) are common arrhythmias associated with significant morbidity and mortality.1,2
Purpose Atrial fibrosis is the main pathological basis for the pathogenesis and progression of atrialfibrillation (AF). Methods PubMed, Web of Science, EMBASE, and Cochrane Library databases were searched systematically from inception through July 1, 2023, to identify relevant studies.
2023 ACC/AHA/ACCP/HRS guidelines suggest that patients with Atrialfibrillation (AF) at intermediate to low annual risk of ischemic stroke can benefit from consideration of factors that might modify their risk of stroke. The role of non-traditional risk factors such as primary hyperparathyroidism (PHPT) remains unexplored.
Ioannis Katsoularis, image courtesy of Klas Sjöberg milla1cf Thu, 12/14/2023 - 09:23 December 14, 2023 — Individuals infected with COVID-19 are also at an increased risk of suffering from heart rhythm disturbances, such as atrialfibrillation.
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment. Stroke is a major concern for millions of people living with atrialfibrillation, and as physicians, we strive to deliver better outcomes for these patients."
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrialfibrillation. ResultsA total of 12 studies included 73,824 patients with atrialfibrillation (average age: 72.67, males: 42,275, 57.3%), among them, there were 7,673 patients combined with thrombocytopenia.
Atrialfibrillation (AF) is a common reversible cause of worsening left ventricular ejection fraction (LVEF) in patients with heart failure. We report and compare the complications in patients with systolic heart failure (LVEF 50% who underwent CA for AF at a large tertiary referral centre between September 2013 and December 2023.
The yield of genetic testing in atrialfibrillation (AF) remains unclear. Based on limited evidence, the 2023 AHA AF guidelines state that it may be reasonable to perform genetic testing in patients with AF onset before 45 years of age without risk factors (class IIb recommendation).
2023 STS Coronary Conference Agenda gtrainyte Tue, 02/14/2023 - 09:13 Session titles and presenters are subject to change. Sabik III, MD, Cleveland, OH, USA Sigrid Sandner, MD, Vienna, Austria David Glineur, MD, PhD, Ottawa, ON, Canada Building an Advanced Coronary Surgery Program Day 1: Saturday, June 3, 2023 7:00 a.m. –
The presence of atrialfibrillation (AF) seems to attenuate the response to cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) in patients with heart failure. 2023 HRS guidelines recommend CRT in patients with sinus rhythm (grade 1 recommendation).
Objective Electrode patch position may not be critical for success when cardioverting atrialfibrillation (AF), but the relevance of applied electrical energy is unclarified. Inclusion criteria were randomised controlled trials using biphasic shock waves and self-adhesive patches, and publication date from 2000 to 2023.
Abstract Atrialfibrillation (AF) is currently defined as symptomatic by asking patients if they are aware of when they are in AF and if they feel better in sinus rhythm. The review is based on a presentation by the senior author during the 2023 16th annual European Cardiac Arrhythmia Society (ECAS) congress in Paris, France.
The 2023 ACC/AHA guidelines recommend anticoagulation for three months post-catheter ablation for atrialfibrillation (AF) and lifelong anticoagulation for patients with CHA2DS2VASc score 2.1
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content